Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib.
Ikezoe
Takayuki
T
Togitani
Kazuto
K
Tasaka
Taizo
T
Nishioka
Chie
C
Yokoyama
Akihito
A
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000473:pathology; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016879:Salvage Therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib